Pharmacologic Management of Chronic Insomnia – Evidence‑Based Guideline Summary

1. First‑Line Therapy

• Cognitive‑behavioral therapy for insomnia (CBT‑I) is the mandatory first‑line treatment for chronic insomnia in all adults, including those ≥ 65 years and those with comorbid depression or anxiety; pharmacologic agents should be added only when CBT‑I is insufficient or unavailable. (Strong recommendation) [@1]
• Shared decision‑making should be used to discuss benefits, harms, and costs of any medication with the patient. [@1][@3]

2. Pharmacologic Options by Symptom Pattern

2.1 Sleep‑Onset Insomnia

• Ramelteon 8 mg is the preferred agent for sleep‑onset difficulty and is considered safe in older adults. [@2]
• Zaleplon 10 mg provides a short‑acting option for sleep‑onset problems. [@2]
• Zolpidem (10 mg for men, 5 mg for women or older adults) is effective for sleep onset; in patients ≥ 65 years the maximum dose should be limited to 5 mg. [@2][@3]
• Triazolam 0.25 mg may be used as a benzodiazepine alternative, but requires cautious use. [@2]

2.2 Sleep‑Maintenance Insomnia

• Suvorexant (orexin‑receptor antagonist) can be used for maintenance insomnia for periods of ≥ 3 months. [@2]
• Low‑dose doxepin 3–6 mg is specifically indicated for sleep‑maintenance difficulty; doses > 6 mg are considered potentially inappropriate in older adults. [@2][@3]

2.3 Both Sleep‑Onset and Maintenance Insomnia

• Eszopiclone 2–3 mg addresses both sleep‑onset and maintenance components. [@2]
• Temazepam 15 mg (benzodiazepine) may be used with caution for combined insomnia symptoms. [@2]

3. Dosing Considerations for Adults ≥ 65 Years

• All hypnotics require dose reduction in older adults because of an increased risk of falls (adjusted OR ≈ 1.7 for fractures) and cognitive impairment. [@3]
• Ramelteon 8 mg does not require dose adjustment in the elderly. [@3]
• Zolpidem should be limited to a maximum of 5 mg regardless of gender. [@3]
• Low‑dose doxepin should not exceed 6 mg. [@3]

4. Duration of Treatment & Intermittent Dosing

• Initial pharmacologic trial should be limited to ≤ 4 weeks; longer use (≥ 3 months) is permissible for orexin‑receptor antagonists (e.g., suvorexant) when justified and monitored. [@3]
• Intermittent (as‑needed) dosing is recommended for chronic insomnia requiring medication—prescribe approximately 7 tablets per month (1–2 nights per week) and advise use only on nights with significant sleep difficulty. [@3]

5. Contra‑indications & Safety Warnings

• Absolute contraindications for hypnotics include severe hepatic impairment, pregnancy, a history of complex sleep‑related behaviors (e.g., sleep‑driving), and compromised respiratory function or untreated sleep apnea. [@3]
• Patients must be counseled about the risk of complex sleep‑related behaviors (especially with zolpidem), next‑morning impairment (avoid driving until fully awake), avoidance of alcohol and other CNS depressants, and taking the medication on an empty stomach with ≥ 7–8 hours planned sleep. [@3]
• Fall risk is markedly increased with benzodiazepines and non‑benzodiazepine receptor agonists in older adults. [@3]

6. Monitoring & Follow‑Up

• Reassess efficacy and adverse effects every few weeks after initiation. [@3]
• If insomnia persists beyond 7–10 days of treatment, evaluate for underlying sleep disorders (e.g., polysomnography) and consider alternative diagnoses. [@2][@3]
• Monitor for withdrawal, rebound insomnia, and abuse potential; orexin antagonists have minimal abuse risk. [@2]

7. Agents Not Recommended (Strong Evidence Against)

• Trazodone ≤ 50 mg – lacks proven benefit and carries significant risks. [@2]
• Diphenhydramine – anticholinergic burden, especially harmful in older adults. [@2]
• Immediate‑release melatonin – insufficient evidence for efficacy. [@2]
• Tiagabine – not effective for insomnia. [@2]
• L‑tryptophan – insufficient evidence. [@2]
• Valerian – benefits are equivocal. [@2]

All statements are derived from cited guideline sources; where multiple citations existed, the non‑Praxis source was prioritized.

Evidence‑Based Pharmacologic Management of Chronic Insomnia

Efficacy of Specific Hypnotics

• Eszopiclone 2–3 mg significantly increases total sleep time by 28–57 minutes and reduces wake time after sleep onset by 10–14 minutes compared with placebo, supported by robust randomized trial data. Strong evidence. 1

Absolute Contraindications for Hypnotic Use

• Pregnancy is an absolute contraindication for all hypnotic agents. Strong recommendation. 1
• Severe hepatic insufficiency, compromised respiratory function, or untreated obstructive sleep apnea constitute absolute contraindications for hypnotic therapy. Strong recommendation. 1

Mandatory Safety Warnings

• Patients must avoid alcohol and other central‑ nervous system depressants while using hypnotics to prevent additive sedation and respiratory depression. Strong recommendation. 1
• Hypnotics should be taken on an empty stomach with an anticipated sleep duration of ≥7–8 hours to reduce next‑day residual effects. Strong recommendation. 1

Observational Risks Associated with Hypnotic Use

• Large observational studies link the use of hypnotics—including benzodiazepines—to a higher risk of dementia, fractures, and major injuries. Moderate‑quality evidence. 1

Guidelines for Gradual Discontinuation (Tapering)

• A tapering schedule reducing the dose by 10–25 % each week (or reducing dosing frequency) is recommended; successful tapering typically requires several weeks to months and should not be rushed. Strong recommendation. 1
• Abrupt cessation after only a few days of hypnotic use can cause rebound insomnia lasting 1–3 days and psychological withdrawal symptoms such as anxiety and irritability. Strong recommendation. 1

Guideline Recommendations for Pharmacologic Management of Primary Insomnia in Adults

First‑Line Non‑Pharmacologic Therapy

• All adults with chronic insomnia should receive cognitive‑behavioral therapy for insomnia (CBT‑I) as the initial treatment before any medication is prescribed; this recommendation is strong and based on moderate‑quality evidence and applies equally to patients ≥ 65 years old. 2
• Pharmacologic agents are to be added only when CBT‑I is insufficient, unavailable, or while awaiting access to behavioral therapy. 2

Sex‑ and Age‑Based Dosing of Zolpidem

• For sleep‑onset insomnia, zolpidem should be dosed at 10 mg for men younger than 65 years, but limited to 5 mg for women (because of slower clearance) and for all adults ≥ 65 years (due to increased fall risk); the FDA mandates these lower doses because of documented driving impairment and cognitive effects. 2

Safety Risks Associated with Chronic Hypnotic Use

• Large observational studies have linked chronic use of hypnotics—including benzodiazepines and “Z‑drugs”—to higher risks of dementia, fractures, and major injuries. 2
• The FDA warns that chronic hypnotic use can cause cognitive and behavioral changes, impaired driving, and motor‑vehicle accidents; these risks are especially pronounced in older adults. 2

Algorithmic Selection Based on Sleep Pattern

• After confirming chronic insomnia and documenting CBT‑I failure or unavailability, clinicians should identify the predominant sleep pattern (sleep‑onset only, sleep‑maintenance only, or combined) to guide pharmacologic choice. 2

  • Sleep‑onset only: consider ramelteon 8 mg or zaleplon 10 mg.
  • Sleep‑maintenance only: consider suvorexant 10–20 mg (15 mg if ≥ 65 years) or low‑dose doxepin 3–6 mg.
  • Combined onset and maintenance: consider eszopiclone 2–3 mg or newer dual orexin‑receptor antagonists (e.g., lemborexant, daridorexant).

• Age‑based dose reductions are required for all hypnotics except ramelteon and the dual orexin‑receptor antagonists. 2 (Note: specific dose‑reduction details are provided elsewhere in the guideline.)

Guideline Recommendations on Trazodone and Alternative Insomnia Therapies

Recommendations Against Trazodone

• The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline recommends that clinicians do not use trazodone for sleep‑onset or sleep‑maintenance insomnia in adults, citing weak evidence of efficacy and a concerning adverse‑effect profile. 3
• The 2020 VA/DoD guideline reports that trazodone showed no difference in sleep efficiency or discontinuation rates compared with placebo, and that low‑quality evidence of benefit is outweighed by its adverse‑effect profile. 4

Evidence on Trazodone Efficacy and Safety

• Reported adverse effects of trazodone include orthostatic hypotension, next‑day sedation, dizziness, and gastrointestinal symptoms, which are especially problematic for mid‑life women who may experience vasomotor instability. 4

Alternative Pharmacologic Options Recommended by AASM

Ramelteon (Melatonin Receptor Agonist)

• The AASM recommends ramelteon 8 mg at bedtime as a safe option for sleep‑onset insomnia; trials of this dose demonstrated efficacy without abuse potential or next‑day cognitive impairment. 3

Low‑Dose Doxepin (Tricyclic Antidepressant)

• The AASM recommends low‑dose doxepin (3–6 mg) at bedtime for sleep‑maintenance insomnia, based on trials showing efficacy at these doses with a favorable safety profile. 3

Suvorexant (Orexin Receptor Antagonist)

• The AASM recommends suvorexant for sleep‑maintenance insomnia, with evidence from trials of 10 mg, 15/20 mg, and 20 mg doses supporting its efficacy and minimal abuse potential. 3

Avoidance of Benzodiazepine Receptor Agonists

• The VA/DoD guideline advises avoiding benzodiazepine receptor agonists (e.g., eszopiclone, zolpidem, zaleplon) in patients with a history of hypnotic overuse, due to a significant risk of dependence and diversion. 4

Monitoring and Further Evaluation

• The VA/DoD guideline suggests that if insomnia persists after an initial pharmacologic trial, clinicians should reassess efficacy and adverse effects every 2–4 weeks and consider polysomnography to rule out underlying sleep disorders such as sleep apnea or periodic limb movements. 4